Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Translocation protein SEC63 homolog (SEC63) is an integral membrane protein that is a key component of the endoplasmic reticulum (ER) Sec61 translocon complex, crucial for the translocation of precursor proteins across the ER membrane[1][3][5]. SEC63 mediates both cotranslational and post-translational import of proteins into the ER and plays an auxiliary role in recognizing substrates with short, hydrophobic signal peptides[1][3][5]. It works in concert with SEC62 and HSPA5/BiP to facilitate the entry of small presecretory proteins into the SEC61 channel, enabling their passage into the ER lumen[1][5]. SEC63 is also implicated in the backward (retrograde) transport of ER proteins destined for ubiquitin-proteasome degradation[3][5]. Mutations in the SEC63 gene cause autosomal dominant polycystic liver disease and can contribute to concurrent polycystic kidney disease[2][5]. There is no current evidence that SEC63 serves as a direct therapeutic target or that any approved drugs interact specifically with this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Translocation protein SEC63 homolog (SEC63).